Breast lesions with atypia in percutaneous biopsies, managed with surgery in the last 10 years

Simple item page
dc.contributor.authorCarrillo, Mitzy
dc.contributor.authorMaturana, Gregorio
dc.contributor.authorMaiz, Cristobal
dc.contributor.authorRomero, Diego
dc.contributor.authorDominguez, Francisco
dc.contributor.authorOddo, David
dc.contributor.authorVillarroel, Alejandra
dc.contributor.authorRazmilic, Dravna
dc.contributor.authorElena Navarro, Maria
dc.contributor.authorLeon, Augusto
dc.contributor.authorSanchez, Cesar
dc.contributor.authorCamus, Mauricio
dc.date.accessioned2025-01-23T21:15:15Z
dc.date.available2025-01-23T21:15:15Z
dc.date.issued2019
dc.description.abstractIntroduction: The optimal management of breast lesions with atypia (BLA), detected in percutaneous biopsies after screening mammograms, is a controversial issue. The aim of this paper is to compare histological diagnosis by percutaneous biopsy with the results of the surgical biopsy of these lesions and to analyse the changes to clinical approach this would imply.
dc.description.abstractMethod: A retrospective study was carried out on patients operated on between June 2007 and June 2017 with a diagnosis of BLA. One hundred and forty-seven patients were identified with a pre-operative diagnosis of flat epithelial atypia (FEA), atypical ductal hyperplasia (ADH), atypical lobular hyperplasia, lobular carcinoma in situ and other atypia.
dc.description.abstractResults: The average age at diagnosis of BLAs was 52 +/- 9.4 years. Radiologically, the lesions presented as microcalcifications in 79%, nodules in 15.6% and other lesions 5.4%. 73.5% of these were biopsied by means of digital stereotaxis. All of the patients analysed underwent a partial mastectomy. Changes in a biologically high-risk lesion were observed in 26.5% of the surgical specimens, of which 75.5% corresponded with ADH and FEA. In the percutaneous biopsies consistent with ADH (40.1%), ductal carcinoma was discovered in 6.8% (5.1% in situ and 1.7% invasive), which implied specific, multi-disciplinary management. Of the FEAs, 84.8% required a second treatment (surgery and/or hormone therapy +/- radiotherapy, depending on whether it concerned FEA 59.6%, ADH 21.2% or ductal carcinoma in situ 3.8%).
dc.description.abstractConclusion: These data show the clinical relevance in the diagnosis of ADH and FEA in percutaneous biopsies. For the diagnosis of FEA in particular, the associated risk of biologically high-risk lesions and ductal carcinoma is made evident.
dc.fuente.origenWOS
dc.identifier.doi10.3332/ecancer.2019.923
dc.identifier.issn1754-6605
dc.identifier.urihttps://doi.org/10.3332/ecancer.2019.923
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/101076
dc.identifier.wosidWOS:000467056700001
dc.language.isoen
dc.revistaEcancermedicalscience
dc.rightsacceso restringido
dc.subjectbreast lesions with atypia
dc.subjectflat epithelial atypia
dc.subjectatypical ductal hyperplasia
dc.subjectatypical lobular hyperplasia
dc.subjectlobular carcinoma in situ
dc.subject.ods05 Gender Equality
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa05 Igualdad de género
dc.subject.odspa03 Salud y bienestar
dc.titleBreast lesions with atypia in percutaneous biopsies, managed with surgery in the last 10 years
dc.typeartículo
dc.volumen13
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas